A study evaluating clinical benefit of 188 Rhenium-HEDP in routine clinical care of painful bone metastases in prostate and breast cancer patients.
Phase of Trial: Phase IV
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Rhenium-188-etidronic acid (Primary)
- Indications Bone metastases
- Focus Adverse reactions; Therapeutic Use
- 03 Apr 2017 New trial record